For the quarter ending 2025-09-30, EVFM made $4,952,000 in revenue. -$1,680,000 in net income. Net profit margin of -33.93%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Product sales, net | 4,952,000 | 4,825,000 | 845,000 | 5,353,500 |
| Cost of goods sold | 905,000 | 755,000 | 365,000 | 1,098,000 |
| Amortization of intangible asset | - | 107,000 | - | - |
| Gain on change in accounting estimates on contingent royalty liability (note 7) | 1,933,000 | - | - | - |
| Amortization of intangible asset | 80,000 | 107,000 | 223,000 | 106,000 |
| Research and development, net | 470,000 | 746,000 | -5,035,000 | - |
| Selling and marketing | 2,391,000 | 2,625,000 | 2,600,000 | 2,275,500 |
| Research and development | - | - | - | 621,500 |
| General and administrative | 2,088,000 | 1,843,000 | 2,365,000 | 3,123,000 |
| Total operating expenses | 4,001,000 | 6,076,000 | 518,000 | 7,277,000 |
| Income (loss) from operations | 951,000 | -1,251,000 | 327,000 | -1,923,500 |
| Interest income | 3,000 | 2,000 | 8,000 | 3,500 |
| Gain on debt extinguishment, net | - | 0 | - | 14,166.667 |
| Loss on issuance of financial instruments | - | 0 | - | -1,091,666.667 |
| Other expense, net | 682,000 | 662,000 | 600,000 | 727,500 |
| Change in fair value of financial instruments | -1,845,000 | 134,000 | 1,221,000 | -198,000 |
| Total other income (expense), net | -2,524,000 | -526,000 | 629,000 | -1,999,500 |
| Loss before income tax benefit (expense) | -1,573,000 | -1,777,000 | 956,000 | -3,923,000 |
| Income tax benefit (expense) | -4,000 | 7,000 | - | - |
| Net loss | -1,569,000 | -1,784,000 | 956,000 | -3,923,000 |
| Convertible and redeemable preferred stock deemed dividends | 111,000 | -1,000 | -3,000 | -26,500 |
| Net loss attributable to common stockholders | -1,680,000 | -1,785,000 | 953,000 | -3,949,500 |
| Net loss per share attributable to common stockholders- basic | -0.01 | -0.02 | 0.01 | -0.06 |
| Net loss per share attributable to common stockholders- diluted | -0.01 | -0.02 | 0 | -0.05 |
| Weighted-average shares used to compute net loss per share attributable to common shareholders - basic | 119,578,093 | 115,686,024 | 113,356,354 | -44,018,409.5 |
| Weighted-average shares used to compute net loss per share attributable to common shareholders - diluted | 119,578,093 | 115,686,024 | 6,039,898,041 | -817,492,859 |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)